약물전달 시스템 시장 : 시장 규모, 점유율 및 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트 및 예측(2025-2034년)

Growth Factors of drug delivery systems Market

The global drug delivery systems market was valued at USD 47.72 billion in 2025 and is projected to grow to USD 49.35 billion in 2026, ultimately reaching USD 70.52 billion by 2034, representing a CAGR of 4.14% during the forecast period. North America dominated the market in 2025 with a 40.53% share, driven by mass COVID-19 vaccination campaigns, increasing hospital admissions, and a strong preference for self-administered drug delivery devices. The U.S. market is expected to reach USD 25.22 billion by 2032, driven by the shift toward home-use and self-administered systems. Key players include BD (Becton Dickinson), Baxter, Gerresheimer AG, Medtronic, Nemera, Kindeva Drug Delivery, West Pharmaceutical Services Inc., and Ypsomed, focusing on innovation, strategic collaborations, and product expansion.

Drug delivery systems are devices designed to introduce drugs into the body while improving efficacy and safety by controlling dosage, timing, and site of release. The market encompasses auto-injectors, syringes, jet injectors, inhalers, and transdermal systems, which are distributed through hospital pharmacies, retail pharmacies, and online channels. The market witnessed a boost during the COVID-19 pandemic due to vaccination drives and increased demand for self-administered devices, although initial hospital access restrictions temporarily slowed growth in 2020.

Market Drivers

Rising Chronic Disease Prevalence: Chronic diseases, including diabetes, cancer, cardiovascular disorders, asthma, and COPD, have been increasing globally, especially among the geriatric population. According to the United Health Foundation, in 2022, 56 million U.S. adults aged 65 and above are susceptible to chronic diseases, boosting the demand for efficient and controlled drug delivery systems.

Shift Toward Advanced Drug Delivery Systems: Patients increasingly prefer advanced systems for their accuracy, targeted delivery, and user-friendliness, particularly self-administered devices. Technologies like on-body platforms, smart insulin pens, and sensor-embedded injectors provide precise dosing, reduce systemic side effects, and enhance therapeutic outcomes. For example, in December 2022, Biocorp received FDA approval for Mallya, a smart sensor that converts insulin pens into connected devices for real-time data collection.

Technological Innovations and Strategic Collaborations: Market growth is supported by product innovations and collaborations. Notable examples include Ypsomed's YpsoMate auto-injector (2021), KINDEVA DRUG DELIVERY's collaboration with CHI for a dry powder inhaler (2021), and Baxter's Novum IQ syringe infusion pump (2022). Companies are focusing on improving convenience, safety, and digital integration of drug delivery devices.

Market Restraints

Regulatory Challenges and Product Recalls: Strict regulatory approval processes and product recalls can limit growth. For instance, in October 2022, Roche recalled the Susvimo eye drug delivery device due to performance issues, and in June 2021, Smiths Medical recalled insulin syringes due to inaccurate markings. Such issues impact trust and slow the introduction of innovative devices.

Market Segmentation

By Type: The injectable segment dominated in 2026 with an 82.83% share, fueled by global vaccination drives, wearable injectors, and rising syringe demand. The inhalation segment is also growing, driven by increasing respiratory disorders and new inhaler product launches.

By Device Type: The conventional segment held a 78.33% share in 2026, attributed to the high adoption of biosimilars and low-cost devices, especially in developing countries. The advanced segment is expected to grow fastest due to enhanced patient compliance, targeted delivery, and technological advancements.

By Distribution Channel: Hospital pharmacies dominate with 63.77% share in 2026, driven by increased hospital visits and infrastructure. Retail pharmacies and online/homecare channels are experiencing growth due to accessibility and convenience.

Regional Insights

• North America: USD 19.34 billion in 2025; projected USD 18.87 billion in 2026. Growth driven by vaccination campaigns, hospital admissions, and adoption of self-administered systems.
• Europe: Significant growth, with the UK projected at USD 2.07 billion and Germany at USD 3.69 billion in 2026, supported by awareness, clinical trials, and new product launches.
• Asia Pacific: Fastest-growing region; Japan USD 2.82 billion, China USD 3.32 billion, and India USD 0.81 billion in 2026, driven by population size, chronic disease prevalence, and expanding manufacturing.
• Latin America & Middle East & Africa: Moderate growth due to increasing healthcare expenditure, hospital admissions, and rising awareness of chronic disease management.

Competitive Landscape

The market is fragmented, with major players like BD, Baxter, Gerresheimer AG, West Pharmaceutical Services Inc., Medtronic, Nemera, Kindeva Drug Delivery, and Ypsomed focusing on product launches, geographical expansion, and manufacturing capacity enhancement. Examples include Nemera's new facility in Poland (2023) and BD Effivax prefillable vaccine syringes (2022).

Conclusion

The global drug delivery systems market is expected to grow from USD 47.72 billion in 2025 to USD 70.52 billion by 2034, driven by rising chronic disease prevalence, increasing patient preference for advanced and self-administered devices, technological innovations, and strategic collaborations. North America leads the market, while Asia Pacific offers the fastest growth. Injectable devices dominate, supported by global vaccination and chronic disease management efforts, whereas advanced drug delivery technologies provide enhanced therapeutic outcomes. Strategic product development, digital integration, and expanding manufacturing capabilities will continue to propel market growth, ensuring better patient compliance and global adoption of innovative drug delivery solutions.

Segmentation By Type

• Inhalation
• Transdermal
• Injectable
• Others

By Device Type

• Conventional
• Advanced

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Region

• North America (By Type, Device Type, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Device Type, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Device Type, Distribution Channel, and Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Device Type, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Device Type, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Drug Delivery Systems
• 4.2. New Product Launches
• 4.3. Key Industry Developments - Mergers, Acquisitions & Partnerships
• 4.4. Impact of COVID-19 on Global Drug Delivery Systems Market

5. Global Drug Delivery Systems Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Inhalation
  • 5.1.2. Transdermal
  • 5.1.3. Injectable
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Device Type
  • 5.2.1. Conventional
  • 5.2.2. Advanced
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail Pharmacies
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Drug Delivery Systems Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Inhalation
  • 6.1.2. Transdermal
  • 6.1.3. Injectable
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Device Type
  • 6.2.1. Conventional
  • 6.2.2. Advanced
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail Pharmacies
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Drug Delivery Systems Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Inhalation
  • 7.1.2. Transdermal
  • 7.1.3. Injectable
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Device Type
  • 7.2.1. Conventional
  • 7.2.2. Advanced
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. France
  • 7.4.2. Italy
  • 7.4.3. Spain
  • 7.4.4. U.K.
  • 7.4.5. Germany
  • 7.4.6. Rest of Europe

8. Asia Pacific Drug Delivery Systems Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Inhalation
  • 8.1.2. Transdermal
  • 8.1.3. Injectable
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Device Type
  • 8.2.1. Conventional
  • 8.2.2. Advanced
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Drug Delivery Systems Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Inhalation
  • 9.1.2. Transdermal
  • 9.1.3. Injectable
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Device Type
  • 9.2.1. Conventional
  • 9.2.2. Advanced
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Drug Delivery Systems Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Inhalation
  • 10.1.2. Transdermal
  • 10.1.3. Injectable
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Device Type
  • 10.2.1. Conventional
  • 10.2.2. Advanced
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis ( 2025)
• 11.2. Company Profiles
  • 11.2.1. Gerresheimer AG
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. BD
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Kindeva Drug Delivery
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Baxter
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. West Pharmaceutical Services Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Ypsomed
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Medtronic
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Nemara
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. E3D Elcam Drug Delivery Devices
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)